| Katie Yeager Plourd, CRNP | |
|
212 4th Ave Se, Suite 300, Cullman, AL 35055-3673 | |
| (205) 271-8312 | |
| (205) 329-7455 |
| Full Name | Katie Yeager Plourd |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 212 4th Ave Se, Cullman, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013259506 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 1-109854 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cullman Regional Medical Center | Cullman, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Birmingham Gastroenterology Associates Pc | 9537107594 | 45 |
News Archive
After a kidney transplant, women may experience decreased kidney damage from ischemia reperfusion injury compared to men due to the impact of gender-specific hormones, suggests a new preclinical study and an analysis of patient data published online in the Journal of Clinical Investigation from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Inovio Pharmaceuticals, Inc. today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced regulatory approval from the China Food and Drug Administration, South Korea's Ministry of Food and Drug Safety, and the Taiwan Food and Drug Administration for the company's REVIVE SE Thrombectomy Device, a next-generation self-expanding clot removal device intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease.
Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.
In a four-year study of Mexican-born women who reside in an agricultural area of California, the worry of deportation appears to double their risk of developing high blood pressure, according to new research published today in the Journal of the American Heart Association, the open access journal of the American Heart Association.
› Verified 2 days ago
| Entity Name | Birmingham Gastroenterology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366406514 PECOS PAC ID: 9537107594 Enrollment ID: O20050420000545 |
News Archive
After a kidney transplant, women may experience decreased kidney damage from ischemia reperfusion injury compared to men due to the impact of gender-specific hormones, suggests a new preclinical study and an analysis of patient data published online in the Journal of Clinical Investigation from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Inovio Pharmaceuticals, Inc. today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced regulatory approval from the China Food and Drug Administration, South Korea's Ministry of Food and Drug Safety, and the Taiwan Food and Drug Administration for the company's REVIVE SE Thrombectomy Device, a next-generation self-expanding clot removal device intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease.
Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.
In a four-year study of Mexican-born women who reside in an agricultural area of California, the worry of deportation appears to double their risk of developing high blood pressure, according to new research published today in the Journal of the American Heart Association, the open access journal of the American Heart Association.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Katie Yeager Plourd, CRNP 1 Independence Plz, Suite 410, Birmingham, AL 35209-2629 Ph: (205) 271-8312 | Katie Yeager Plourd, CRNP 212 4th Ave Se, Suite 300, Cullman, AL 35055-3673 Ph: (205) 271-8312 |
News Archive
After a kidney transplant, women may experience decreased kidney damage from ischemia reperfusion injury compared to men due to the impact of gender-specific hormones, suggests a new preclinical study and an analysis of patient data published online in the Journal of Clinical Investigation from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Inovio Pharmaceuticals, Inc. today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced regulatory approval from the China Food and Drug Administration, South Korea's Ministry of Food and Drug Safety, and the Taiwan Food and Drug Administration for the company's REVIVE SE Thrombectomy Device, a next-generation self-expanding clot removal device intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease.
Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.
In a four-year study of Mexican-born women who reside in an agricultural area of California, the worry of deportation appears to double their risk of developing high blood pressure, according to new research published today in the Journal of the American Heart Association, the open access journal of the American Heart Association.
› Verified 2 days ago
Christopher Michael Kelsey, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1912 Al Highway 157, Cullman, AL 35058 Phone: 256-737-2095 Fax: 256-737-2097 | |
Jennifer Lynn Anderson, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1800 Al Highway 157 Ste 101, Cullman, AL 35058 Phone: 256-739-4131 Fax: 256-739-6027 | |
Stacey S Varden, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1890 Al Highway 157 Ste 300, Cullman, AL 35058 Phone: 256-737-8000 Fax: 256-737-8058 | |
Erika Lancaster, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 503 Clark St Ne, Cullman, AL 35055 Phone: 256-739-0801 | |
Mrs. Melanie Beth Walker, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1800 Al Highway 157 Ste 100, Cullman, AL 35058 Phone: 256-736-5505 Fax: 256-736-5551 | |
Carol A Livingston, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 117 2nd Ave Se, Cullman, AL 35055 Phone: 256-739-4144 Fax: 256-739-0445 |